Two anticancer drugs that target a very small number of lung cancer patients with EGFR exon 20 insertion mutation for which existing TKIs were ineffective, were both unable to receive reimbursement in Korea.

According to industry sources, no reimbursement standards were set for both Takeda Pharmaceuticals Korea’s ‘Exkivity (mobocertinib)’ and Janssen Korea’s ‘ Rybrevant (amivantamab)’ w at the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee meeting that had been held on the 30th. This is the second time Rybrevant failed to establish reimbursement standards at the CDDC level.

EGFR exon 20 insertion mutations in NSCLC are so rare that it is fo